Patents by Inventor Tatiana Novobrantseva

Tatiana Novobrantseva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 And VEGF Genes
    Publication number: 20140288154
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a lipid formulation, and methods of using the compositions to inhibit the expression of the Human kinesin family member 11 (Eg5) and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
    Type: Application
    Filed: June 9, 2014
    Publication date: September 25, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Akin Akinc, Dinah Wen-Yee Sah, Tatiana Novobrantseva
  • Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
    Publication number: 20140243394
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Application
    Filed: May 15, 2014
    Publication date: August 28, 2014
    Applicants: Alnylam Pharmaceuticals Inc., The Government of the United States, as Represented by the Secretary of the Army
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • METHODS FOR USE WITH BAFF ANTAGONISTS
    Publication number: 20140213470
    Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.
    Type: Application
    Filed: November 21, 2013
    Publication date: July 31, 2014
    Applicants: GENENTECH, INC., BIOGEN IDEC MA INC.
    Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
  • Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene
    Publication number: 20140179759
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA
    Type: Application
    Filed: August 28, 2013
    Publication date: June 26, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
    Publication number: 20140148497
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Application
    Filed: July 10, 2013
    Publication date: May 29, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • Compositions and methods for inhibiting expression of a gene from the Ebola virus
    Patent number: 8735369
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: May 27, 2014
    Assignees: Alnylam Pharmaceuticals, Inc., The United States of America, as represented by the Secretary of the Army
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • Compositions and methods for inhibiting expression of factor VII gene
    Patent number: 8664193
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 4, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Akin Akinc
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KLF-1 AND BCL11A GENES
    Publication number: 20140018410
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the KLF1 gene and the BCL11A gene, and methods of using such dsRNA compositions to inhibit expression of KLF1 and BCL11 A, respectively.
    Type: Application
    Filed: December 9, 2011
    Publication date: January 16, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Tatiana Novobrantseva, Brian Bettencourt, Stuart Milstein, Anna Borodovsky
  • Methods for use with BAFF antagonists
    Patent number: 8617545
    Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: December 31, 2013
    Assignees: Biogen Idec MA Inc., Genentech, Inc.
    Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
  • Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
    Patent number: 8546554
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: October 1, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • Compositions And Methods for Inhibiting Expression Of A Gene From the Ebola Virus
    Publication number: 20130225654
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Application
    Filed: September 26, 2012
    Publication date: August 29, 2013
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • Compositions and methods for inhibiting expression of CD274/PD-L1 gene
    Patent number: 8507663
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: August 13, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin Defougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENE
    Publication number: 20130184326
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
    Type: Application
    Filed: September 14, 2012
    Publication date: July 18, 2013
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Akin Akinc
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20130158097
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: June 2, 2011
    Publication date: June 20, 2013
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE
    Publication number: 20130065943
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 14, 2013
    Inventors: Antonin De Fougerolles, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Sina Bavari, Kelly Lyn Warfield
  • Compositions and methods for inhibiting expression of a gene from the ebola virus
    Patent number: 8354390
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: January 15, 2013
    Assignees: Alnylam Pharmaceuticals, Inc., The United States of America, as represented by the Secretary of the Army
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • Compositions and methods for inhibiting expression of factor VII gene
    Patent number: 8334273
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: December 18, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Akin Akinc
  • Lipid Formulated Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
    Publication number: 20120270921
    Abstract: The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Application
    Filed: August 13, 2010
    Publication date: October 25, 2012
    Inventors: Antonin de Fougerolles, Anna Borodovsky, Tatiana Novobrantseva
  • Compositions and methods for inhibiting expression of CD45 gene
    Patent number: 8288525
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: October 16, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Sina Bavari, Kelly Lyn Warfield
  • SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS
    Publication number: 20120225434
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: May 1, 2012
    Publication date: September 6, 2012
    Applicants: ALNYLAM PHARMACEUTICALS, INC., The University of British Columbia, Tekmira Pharmaceuticals Corporation
    Inventors: Marco A. CIUFOLINI, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis